Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | TERT | O14746 | 6/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23075124 | 0.85 | CNR1 (0.69) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL5418745 | 0.84 | ROCK2 (0.68) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL5413020 | 0.84 | ROCK2 (0.65) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL22590401 | 0.83 | CNR1 (0.77) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL5407357 | 0.83 | ROCK2 (0.63) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL5411112 | 0.83 | P2RX7 (0.65) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL17776529 | 0.82 | ROCK2 (0.71) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL22590465 | 0.82 | ROCK2 (0.63) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL5415164 | 0.82 | ROCK2 (0.63) | ROCK2ROCK1CNR1CNR2P2RX7 | |
| SCHEMBL5401733 | 0.82 | ROCK2 (0.63) | ROCK2ROCK1CNR1CNR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885CNR1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.